Armata Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
Armata Pharmaceuticals reports positive Phase 2a data for AP-SA02 in complicated S. aureus bacteremia, receives QIDP designation, and plans for Phase 3, but faces substantial doubt about its ability to continue as a going concern.
AMEX
10-K: Armata Pharmaceuticals Reports 2024 Results, Highlights Clinical Progress and Financial Strategy
Armata Pharmaceuticals' 2024 10-K filing details clinical trial advancements, financial results, and strategic financing activities in the development of bacteriophage therapies.
AMEX
Armata Pharmaceuticals has formalized a policy to recover incentive-based compensation from executives in the event of financial restatements.